Five health systems have joined the Strata Precision Oncology Network—Baptist Health in Kentucky, Lehigh Valley Health Network in Pennsylvania, Marshfield Clinic in Wisconsin, MultiCare Health System in Washington, and Prisma Health in South Carolina.
According to a report on state-level engagement in cancer, by the American Cancer Society Cancer Action Network Texas met policy recommendations in only two of the eight evaluated issue areas.
TCR2 Therapeutics Inc. announced it has entered into a Cooperative Research and Development Agreement with NCI to collaborate on the use of TCR2's proprietary T cell receptor Fusion Construct T cells as a cancer therapeutic agent against mesothelin in the Company's ongoing phase I/II trial of TC-210.
The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has formed the Pelotonia Institute for Immuno-Oncology, a bench-to-bedside research initiative focused on harnessing the body's immune system to fight cancer at all levels—from prevention to treatment and survivorship.
NYU Langone Health's Ronald O. Perelman Department of Dermatology has received a five-year, $11 million NCI grant to design tools that predict whether therapies that help the immune system fight cancer will be effective for a specific patient.
Andrew Venteicher was named director of the Center for Cranial Base Surgery at the University of Minnesota Medical School's Department of Neurosurgery and the Masonic Cancer Center, where he will be leading key research initiatives in the genomics of brain tumors.
The Biden Cancer Initiative July 15 announced that it has suspended operations.
David Callender was named president and CEO of the Memorial Hermann Health System effective Sept. 1.
Anixa Biosciences Inc. and Cleveland Clinic have formed a strategic alliance and license agreement for breast cancer vaccine technology.
FDA announced the availability of a draft guidance for industry, “Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues.”
